[117]
Novopharm submits that the toxicity data set out for the racemic mixture in the '080 patent is inconsistent with the toxicity data previously reported by the inventors in the ofloxacin '840 patent, claiming the racemate. Novopharm points out several deficiencies in Dr. Arnott's knowledge of the toxicity studies performed for the '840 and '080 patents which were brought out on cross-examination. The respondent relies on
Lundbeck (H.) A/S et al. v. Canada (Minister of Health) et al.
, [2003] F.T.R. Uned. 943; 30 C.P.R.(4th) 198; 2003 FC 1334, where it was recently affirmed that the allegations set out in the NOA are presumed to be true except to the extent that they are disproved by the applicant.